Cabergoline in Nonfunctioning Pituitary Adenomas

• Status: Completed
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended. We will evaluate the use of cabergoline in a clinical trial, in order to define the efficacy of this treatment in nonfunctioning pituitary adenoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sao Paulo General Hospital
• Treatments: Cabergoline

Criteria

Inclusion Criteria:

• presence of pituitary tumor rest at 6 months after neurosurgery

• absence of previous hormonal pituitary hypersecretion

• absence of previous radiotherapy and/or radiosurgery

• Histopathological exam showing pituitary adenoma

Exclusion Criteria:

• ACTH immunoexpression at histopathological exam

• presence of previous radiotherapy and/or radio surgery

• psychotic psychiatric disease

• moderate or severe alterations in cardiac valves